Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hematopoietic transcription factor LIM domain only 2 (LMO2), a member of the TAL1 transcriptional complex, plays an essential role during early hematopoiesis and is frequently activated in T-cell acute lymphoblastic leukemia (T-ALL) patients.
|
31366618 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LMO2 directly associates with LDB1 in a large DNA-containing nuclear complex and controls the transcription of T-ALL-related genes.
|
29278703 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis.
|
29778661 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BACKGROUND The human LMO2 gene was first cloned from an acute T lymphocytic leukemia patient; it is primarily expressed in hematopoietic and vascular endothelial systems, and functions as a pivotal transcriptional regulator during embryonic hematopoiesis and angiogenesis.
|
28170369 |
2017 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LMO2 is traditionally recognized as a pivotal transcriptional regulator during embryonic hematopoiesis and angionenesis, and its ectopic expression in T lymphocyte progenitors is closely correlated to the onset of acute T lymphocytic leukemia.
|
27880729 |
2017 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Foxp3 could interact with LMO2 and affect the expression level of TAL1, which was in accordance with the findings in T-cell acute lymphoblastic leukemia.
|
27574108 |
2016 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, compound heterozygotes displayed an accelerated onset of T-ALL compared with mice carrying the Lmo2 oncogene alone.
|
27118408 |
2016 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we demonstrate that FOXP3 binds LMO2 in vitro, resulting in decreased interaction between LMO2 and TAL1, providing a molecular mechanism for FOXP3-mediated transcriptional modulation in T-ALL.
|
26686090 |
2016 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Subsequent studies on its role in tumours and in normal settings have highlighted LMO2 as an archetypical chromosomal translocation oncogene, activated by association with antigen receptor gene loci and a paradigm for translocation gene activation in T-ALL.
|
26108219 |
2015 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
|
24394663 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seven patients developed acute leukemia [one acute myeloid leukemia (AML), four T cell acute lymphoblastic leukemia (T-ALL), and two primary T-ALL with secondary AML associated with a dominant clone with vector integration at the LMO2 (six T-ALL), MDS1 (two AML), or MN1 (one AML) locus].
|
24622513 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the LMO2-LYL1 interaction is a promising therapeutic target for inhibiting self-renewing cancer stem cells in T-ALL, including poor-prognosis ETP-ALL cases.
|
23926305 |
2013 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
One patient developed acute T cell acute lymphoblastic leukemia because of up-regulated expression of the proto-oncogene LMO-2 from insertional mutagenesis, but maintained a polyclonal T cell repertoire through chemotherapy and entered remission.
|
21865537 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In T-lymphocytes, aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia, while in B cells LMO2 is also expressed in germinal center lymphocytes and diffuse large B-cell lymphomas, where it predicts better clinical outcome.
|
21459790 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thymic expression of the Tal1 and Lmo2 oncogenes in mice results in rapid development of T-ALL; and similar to T-ALL patients, more than half the leukemic mice develop spontaneous mutations in Notch1.
|
21670468 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The gene encoding LIM-only 2 (LMO2), an oncogenic transcription factor, is frequently activated in T cell acute lymphoblastic leukemia (T-ALL), but how LMO2 transforms primary hematopoietic cells to induce T-ALL remains an open question.McCormack et al. now show that, in mice, Lmo2 confers self-renewal potential on normally nonrenewing thymocyte progenitor cells, and this property is maintained over four serial transplantations when the cells are transplanted into irradiated mice that lack thymocytes.
|
20374994 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lmo2 induced self-renewal of committed T cells in the mice more than 8 months before the development of overt T-ALL.
|
20093438 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.
|
20861166 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
|
19246562 |
2009 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the position of the LMO2 breakpoints in T-ALL in the light of the occurrence of TCRD-LMO2 translocations in normal thymocytes points to a critical role for the exact breakpoint location in determining LMO2 activation levels and the consequent pressure for T-ALL development.
|
17360939 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we debate whether the integration near the LMO2 locus is sufficient to result in T-ALL-like proliferations or whether the gamma-retroviral viral expression of the therapeutic IL2RG gene contributes to leukemogenesis.
|
17726455 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data help explain why LMO2 was preferentially targeted over many of the other known T-ALL oncogenes.
|
17268520 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
LMO2 abnormalities represent about 9% (13/138) of pediatric T-ALL cases and are more frequent in pediatric T-ALL than appreciated until now.
|
16873670 |
2006 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LMO2 abnormalities represent about 9% (13/138) of pediatric T-ALL cases and are more frequent in pediatric T-ALL than appreciated until now.
|
16873670 |
2006 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we find that retroviral overexpression of IL2RG in human CD34+ cells has no effect on T-cell development, whereas overexpression of the T-cell acute lymphoblastic leukaemia (T-ALL) oncogene LMO2 leads to severe abnormalities.
|
16988660 |
2006 |